Cargando…

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation

BACKGROUND: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. OBJECTIVES: There are limited data on the efficacy of ICIs according to KRAS m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Sun Young, Hong, Jung Yong, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Jang, Jae Yeon, Jeon, Youngkyung, Kim, Seung Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164250/ https://www.ncbi.nlm.nih.gov/pubmed/37163165 http://dx.doi.org/10.1177/17562848231170484

Ejemplares similares

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
por: Kim, Seung Tae, et al.
Publicado: (2015)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms
por: Jeong, Sun Young, et al.
Publicado: (2023)

KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers
por: Yokoyama, Masaaki, et al.
Publicado: (2016)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Bile Acid Analysis in Biliary Tract Cancer
por: Park, Jeong Youp, et al.
Publicado: (2006)

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
por: Kim, Hae Su, et al.
Publicado: (2016)

Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Medical disputes related to advanced endoscopic procedures with endoscopic retrograde cholangiopancreatography or endoscopic ultrasonography for the management of pancreas and biliary tract diseases
por: Lee, Yoon Suk, et al.
Publicado: (2023)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer
por: Kwon, Sung Chan, et al.
Publicado: (2023)

Predictive Factors of Biliary Tract Cancer in Anomalous Union of the Pancreaticobiliary Duct
por: Park, Jin-Seok, et al.
Publicado: (2016)

Prognostic Role of KRAS mRNA Expression in Breast Cancer
por: Hwang, Ki-Tae, et al.
Publicado: (2019)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
por: Yoon, Kyong-Ah, et al.
Publicado: (2018)

Zebrafish model of KRAS-initiated pancreatic endocrine tumor
por: Oh, Sekyung, et al.
Publicado: (2019)

Oncogenic KRAS–expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice
por: Kasuga, Akiyoshi, et al.
Publicado: (2021)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis
por: Lee, Hee Seung, et al.
Publicado: (2018)

Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
por: Lee, Seung Eun, et al.
Publicado: (2016)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
por: Yoo, Changhoon, et al.
Publicado: (2021)

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer
por: Kang, Jihoon, et al.
Publicado: (2023)

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
por: Ji, Jun Ho, et al.
Publicado: (2018)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
por: Park, Hyung Soon, et al.
Publicado: (2017)

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
por: Cho, Jang Ho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eafhcilql7kfe6jbd89s8tfqdr